Introduction Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal
multimodality therapy. The challenge lies in their early recognition and timely management …

Abstract Purpose Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are
challenging for their invasive nature, resistance to treatment and recurrences …

Context Despite growing evidence that temozolomide (TMZ) therapy is effective for the
treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy …

Background Treatment of aggressive pituitary adenomas typically involves a multimodality
approach based on histopathological features and may include pharmacotherapy, surgery …

Introduction Pituitary adenomas can show a tendency to grow, despite multimodal treatment.
Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary …

Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …

Background Pituitary carcinomas (PC) and atypical pituitary adenomas (APA) are rare
variants of pituitary tumors for which no evidence-based treatment currently exists. We …

The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT)
has revolutionised clinical practice in this field with significantly improved clinical outcomes …

Objective To collect outcome data in a large cohort of patients with aggressive pituitary
tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …